Short answer
Denali Therapeutics Inc. (DNLI) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $4M with net income of −$128M.
Q2 2026 key financials · XBRL
- Revenue
- $4M
- Net income
- −$128M
- −2.8% YoY · +0.7% QoQ
- Operating margin
- -3622.1%
- EPS (diluted)
- −$0.68
- +5.6% YoY · +1.4% QoQ
Source: XBRL data from the Denali Therapeutics Inc. (DNLI) Q2 2026 10-Q on SEC EDGAR. USD.
Denali Therapeutics Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $3.6M, versus $0 prior-year quarter, driven by AVLAYAH commercial launch
- Operating loss $130.5M, with operating margin -3,624.4% versus not meaningful prior-year margin
- Net loss $127.6M versus $124.1M, with net margin -3,539.3% versus not meaningful
- Best-performing product AVLAYAH, generating $3.6M revenue; no other commercial products
- PRV sale generated $195.0M gross proceeds, received July 2026; Royalty Pharma funding added $200.0M gross proceeds in March
- Continued operating losses expected as AVLAYAH commercialization and clinical programs advance; Takeda collaboration termination and failed LUMA endpoints emerging headwinds
Risk Factors
- No risk-factors section provided; supplied text covers Items 2–6 rather than changed or carried-forward risks
- Financing risk: $499.3 million private-placement proceeds subject to dilution from 26,046,065 pre-funded warrants
- Compliance risk: private placement relies on Section 4(a)(2) and Rule 506(b) Regulation D exemptions
- Governance risk: investor received director-nomination and additional registration rights
- Market risk: director trading plan permits sales of up to 35,377 shares through September 2, 2027
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Denali Therapeutics Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.